RHOEN-KLINIKUM AG (RHK.DE) Stock Fundamental Analysis

FRA:RHK • DE0007042301

13 EUR
-0.1 (-0.76%)
Last: Feb 26, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to RHK. RHK was compared to 30 industry peers in the Health Care Providers & Services industry. RHK has an excellent financial health rating, but there are some minor concerns on its profitability. RHK is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • In the past year RHK was profitable.
  • RHK had a positive operating cash flow in the past year.
  • RHK had positive earnings in each of the past 5 years.
  • RHK had a positive operating cash flow in each of the past 5 years.
RHK.DE Yearly Net Income VS EBIT VS OCF VS FCFRHK.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

1.2 Ratios

  • With a Return On Assets value of 2.02%, RHK perfoms like the industry average, outperforming 43.33% of the companies in the same industry.
  • The Return On Equity of RHK (2.90%) is worse than 63.33% of its industry peers.
  • RHK has a Return On Invested Capital of 2.67%. This is in the lower half of the industry: RHK underperforms 70.00% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for RHK is below the industry average of 6.83%.
  • The last Return On Invested Capital (2.67%) for RHK is above the 3 year average (2.34%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 2.02%
ROE 2.9%
ROIC 2.67%
ROA(3y)2%
ROA(5y)1.56%
ROE(3y)2.83%
ROE(5y)2.2%
ROIC(3y)2.34%
ROIC(5y)2.01%
RHK.DE Yearly ROA, ROE, ROICRHK.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2 4 6

1.3 Margins

  • RHK has a Profit Margin of 2.28%. This is comparable to the rest of the industry: RHK outperforms 46.67% of its industry peers.
  • RHK's Profit Margin has declined in the last couple of years.
  • RHK has a Operating Margin of 2.86%. This is in the lower half of the industry: RHK underperforms 66.67% of its industry peers.
  • In the last couple of years the Operating Margin of RHK has declined.
  • With a decent Gross Margin value of 66.81%, RHK is doing good in the industry, outperforming 70.00% of the companies in the same industry.
  • RHK's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 2.86%
PM (TTM) 2.28%
GM 66.81%
OM growth 3Y11.39%
OM growth 5Y-7.03%
PM growth 3Y10.42%
PM growth 5Y-3.92%
GM growth 3Y-1.4%
GM growth 5Y-0.67%
RHK.DE Yearly Profit, Operating, Gross MarginsRHK.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • RHK has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • RHK has about the same amout of shares outstanding than it did 1 year ago.
  • RHK has about the same amout of shares outstanding than it did 5 years ago.
  • RHK has a better debt/assets ratio than last year.
RHK.DE Yearly Shares OutstandingRHK.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
RHK.DE Yearly Total Debt VS Total AssetsRHK.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • RHK has an Altman-Z score of 3.08. This indicates that RHK is financially healthy and has little risk of bankruptcy at the moment.
  • With an excellent Altman-Z score value of 3.08, RHK belongs to the best of the industry, outperforming 83.33% of the companies in the same industry.
  • RHK has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
  • RHK has a better Debt to Equity ratio (0.09) than 96.67% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z 3.08
ROIC/WACC0.4
WACC6.61%
RHK.DE Yearly LT Debt VS Equity VS FCFRHK.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

  • RHK has a Current Ratio of 2.28. This indicates that RHK is financially healthy and has no problem in meeting its short term obligations.
  • RHK has a better Current ratio (2.28) than 96.67% of its industry peers.
  • RHK has a Quick Ratio of 2.19. This indicates that RHK is financially healthy and has no problem in meeting its short term obligations.
  • RHK's Quick ratio of 2.19 is amongst the best of the industry. RHK outperforms 96.67% of its industry peers.
Industry RankSector Rank
Current Ratio 2.28
Quick Ratio 2.19
RHK.DE Yearly Current Assets VS Current LiabilitesRHK.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The earnings per share for RHK have decreased strongly by -15.41% in the last year.
  • RHK shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 0.03% yearly.
  • RHK shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.10%.
  • RHK shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.12% yearly.
EPS 1Y (TTM)-15.41%
EPS 3Y15.28%
EPS 5Y0.03%
EPS Q2Q%3.33%
Revenue 1Y (TTM)9.1%
Revenue growth 3Y4.41%
Revenue growth 5Y4.12%
Sales Q2Q%8.37%

3.2 Future

  • RHK is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.14% yearly.
  • RHK is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.53% yearly.
EPS Next Y4.3%
EPS Next 2Y10.47%
EPS Next 3Y11.09%
EPS Next 5Y11.14%
Revenue Next Year6.74%
Revenue Next 2Y5.36%
Revenue Next 3Y6.5%
Revenue Next 5Y5.53%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RHK.DE Yearly Revenue VS EstimatesRHK.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 500M 1B 1.5B 2B
RHK.DE Yearly EPS VS EstimatesRHK.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0.2 0.4 0.6 0.8 1

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 22.81, the valuation of RHK can be described as rather expensive.
  • Compared to the rest of the industry, the Price/Earnings ratio of RHK is on the same level as its industry peers.
  • Compared to an average S&P500 Price/Earnings ratio of 27.07, RHK is valued at the same level.
  • RHK is valuated rather expensively with a Price/Forward Earnings ratio of 17.01.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of RHK is on the same level as its industry peers.
  • RHK's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 28.05.
Industry RankSector Rank
PE 22.81
Fwd PE 17.01
RHK.DE Price Earnings VS Forward Price EarningsRHK.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, RHK is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.45
RHK.DE Per share dataRHK.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates RHK does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)5.3
PEG (5Y)670.67
EPS Next 2Y10.47%
EPS Next 3Y11.09%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

2

5. Dividend

5.1 Amount

  • RHK has a yearly dividend return of 0.77%, which is pretty low.
  • RHK's Dividend Yield is comparable with the industry average which is at 1.55.
  • Compared to an average S&P500 Dividend Yield of 1.82, RHK's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.77%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
RHK.DE Yearly Dividends per shareRHK.DE Yearly Dividends per shareYearly Dividends per share 2019 2023 2025 0.05 0.1 0.15 0.2 0.25

5.3 Sustainability

  • 17.78% of the earnings are spent on dividend by RHK. This is a low number and sustainable payout ratio.
DP17.78%
EPS Next 2Y10.47%
EPS Next 3Y11.09%
RHK.DE Yearly Income VS Free CF VS DividendRHK.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M
RHK.DE Dividend Payout.RHK.DE Dividend Payout, showing the Payout Ratio.RHK.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

RHOEN-KLINIKUM AG

FRA:RHK (2/26/2026, 7:00:00 PM)

13

-0.1 (-0.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-06
Earnings (Next)03-26
Inst Owners0.55%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap870.48M
Revenue(TTM)1.69B
Net Income(TTM)37.68M
Analysts74.29
Price Target14.45 (11.15%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.77%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP17.78%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-4.43%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.72%
Valuation
Industry RankSector Rank
PE 22.81
Fwd PE 17.01
P/S 0.53
P/FCF N/A
P/OCF 14.11
P/B 0.67
P/tB 0.77
EV/EBITDA 0.45
EPS(TTM)0.57
EY4.38%
EPS(NY)0.76
Fwd EY5.88%
FCF(TTM)-0.12
FCFYN/A
OCF(TTM)0.92
OCFY7.09%
SpS24.7
BVpS19.41
TBVpS16.81
PEG (NY)5.3
PEG (5Y)670.67
Graham Number15.78
Profitability
Industry RankSector Rank
ROA 2.02%
ROE 2.9%
ROCE 3.25%
ROIC 2.67%
ROICexc 4.45%
ROICexgc 5.55%
OM 2.86%
PM (TTM) 2.28%
GM 66.81%
FCFM N/A
ROA(3y)2%
ROA(5y)1.56%
ROE(3y)2.83%
ROE(5y)2.2%
ROIC(3y)2.34%
ROIC(5y)2.01%
ROICexc(3y)3.1%
ROICexc(5y)2.62%
ROICexgc(3y)3.7%
ROICexgc(5y)3.13%
ROCE(3y)2.85%
ROCE(5y)2.44%
ROICexgc growth 3Y17.7%
ROICexgc growth 5Y-1.56%
ROICexc growth 3Y17.75%
ROICexc growth 5Y-1.75%
OM growth 3Y11.39%
OM growth 5Y-7.03%
PM growth 3Y10.42%
PM growth 5Y-3.92%
GM growth 3Y-1.4%
GM growth 5Y-0.67%
F-Score6
Asset Turnover0.89
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA 1.07
Cap/Depr 112.99%
Cap/Sales 4.21%
Interest Coverage 14.78
Cash Conversion 56.66%
Profit Quality N/A
Current Ratio 2.28
Quick Ratio 2.19
Altman-Z 3.08
F-Score6
WACC6.61%
ROIC/WACC0.4
Cap/Depr(3y)97.27%
Cap/Depr(5y)108.32%
Cap/Sales(3y)4.24%
Cap/Sales(5y)5.08%
Profit Quality(3y)86.55%
Profit Quality(5y)290.53%
High Growth Momentum
Growth
EPS 1Y (TTM)-15.41%
EPS 3Y15.28%
EPS 5Y0.03%
EPS Q2Q%3.33%
EPS Next Y4.3%
EPS Next 2Y10.47%
EPS Next 3Y11.09%
EPS Next 5Y11.14%
Revenue 1Y (TTM)9.1%
Revenue growth 3Y4.41%
Revenue growth 5Y4.12%
Sales Q2Q%8.37%
Revenue Next Year6.74%
Revenue Next 2Y5.36%
Revenue Next 3Y6.5%
Revenue Next 5Y5.53%
EBIT growth 1Y2.05%
EBIT growth 3Y16.29%
EBIT growth 5Y-3.2%
EBIT Next Year147.27%
EBIT Next 3Y44.19%
EBIT Next 5Y27.48%
FCF growth 1Y26.17%
FCF growth 3Y42.66%
FCF growth 5YN/A
OCF growth 1Y42.49%
OCF growth 3Y9.38%
OCF growth 5Y21.95%

RHOEN-KLINIKUM AG / RHK.DE FAQ

Can you provide the ChartMill fundamental rating for RHOEN-KLINIKUM AG?

ChartMill assigns a fundamental rating of 5 / 10 to RHK.DE.


What is the valuation status of RHOEN-KLINIKUM AG (RHK.DE) stock?

ChartMill assigns a valuation rating of 2 / 10 to RHOEN-KLINIKUM AG (RHK.DE). This can be considered as Overvalued.


Can you provide the profitability details for RHOEN-KLINIKUM AG?

RHOEN-KLINIKUM AG (RHK.DE) has a profitability rating of 4 / 10.


Can you provide the financial health for RHK stock?

The financial health rating of RHOEN-KLINIKUM AG (RHK.DE) is 7 / 10.


How sustainable is the dividend of RHOEN-KLINIKUM AG (RHK.DE) stock?

The dividend rating of RHOEN-KLINIKUM AG (RHK.DE) is 2 / 10 and the dividend payout ratio is 17.78%.